• $502,000 purchase order for HIV Self-Tests
• Manufactured under Mylan brand, funded by Global Fund
• Planned for supply in March 2026
• Continued demand for Atomo's HIV Self-Test in Africa

Atomo Diagnostics Limited (ASX:AT1) has announced that it has secured a purchase order for $502,000 worth of HIV Self-Tests. The tests will be manufactured by Atomo under the Mylan brand and paid for with funding from the Global Fund, with the order planned for supply in March 2026. Atomo considers the revenue from this order to be material. Atomo's Managing Director, John Kelly, expressed delight at the continued demand for the company's HIV Self-Test in Africa, where access to reliable and discreet HIV testing remains critical. The announcement was authorised by the Managing Director & CEO. Atomo is an Australian medical device company that supplies unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market, with a focus on simplifying testing procedures, enhancing usability, and improving reliability across rapid point-of-care (POC) and at-home testing applications.